BTK blockers make headway in multiple sclerosis
Elie Dolgin • January 11, 2021
By targeting both arms of the immune system, not just B cells, brain-penetrant inhibitors of Bruton’s tyrosine kinase could improve on anti-CD20 therapy for patients with multiple sclerosis.
Continue reading at Nature Biotechnology.
Jaw-dropping patient videos and miraculous testimonials ignited a frenzy in China over a technique that aims to improve drainage from the brain. Now it is entering trials worldwide.
But politics could derail the one thing to unlock it.